Condition
Nephrotic Syndrome Steroid-Dependent
Total Trials
5
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Recruiting1
Withdrawn1
Terminated1
Unknown1
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07091175Phase 2Recruiting
Dupilumab Therapy in Nephrotic Syndrome in Children
NCT06792448Not Yet RecruitingPrimary
Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study
NCT04585152Phase 2UnknownPrimary
Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.
NCT04402580Phase 2TerminatedPrimary
Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome
NCT02997150Phase 2WithdrawnPrimary
Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2: a Pilot Study
Showing all 5 trials